CZ303096B6 - Lécivo pro lécení karcinomu prsu obsahující fulvestrant - Google Patents

Lécivo pro lécení karcinomu prsu obsahující fulvestrant Download PDF

Info

Publication number
CZ303096B6
CZ303096B6 CZ20023309A CZ20023309A CZ303096B6 CZ 303096 B6 CZ303096 B6 CZ 303096B6 CZ 20023309 A CZ20023309 A CZ 20023309A CZ 20023309 A CZ20023309 A CZ 20023309A CZ 303096 B6 CZ303096 B6 CZ 303096B6
Authority
CZ
Czechia
Prior art keywords
treatment
fulvestrant
lesions
breast cancer
study
Prior art date
Application number
CZ20023309A
Other languages
Czech (cs)
English (en)
Other versions
CZ20023309A3 (cs
Inventor
Thurlimann@Beat
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ303096(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CZ20023309A3 publication Critical patent/CZ20023309A3/cs
Publication of CZ303096B6 publication Critical patent/CZ303096B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ20023309A 2000-04-05 2001-04-02 Lécivo pro lécení karcinomu prsu obsahující fulvestrant CZ303096B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy

Publications (2)

Publication Number Publication Date
CZ20023309A3 CZ20023309A3 (cs) 2003-02-12
CZ303096B6 true CZ303096B6 (cs) 2012-04-04

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20023309A CZ303096B6 (cs) 2000-04-05 2001-04-02 Lécivo pro lécení karcinomu prsu obsahující fulvestrant

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1586323A1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210898A (pt) * 2001-07-07 2004-06-22 Astrazeneca Ab Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
KR20140048881A (ko) * 2011-05-09 2014-04-24 유니버시티 오브 버지니아 페이턴트 파운데이션 암 치료 조성물 및 방법
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI878810B (zh) 2017-09-11 2025-04-01 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
CA3101421C (en) * 2018-05-24 2024-06-18 Kashiv Biosciences, Llc Prodrugs of fulvestrant
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2021174195A2 (en) * 2020-02-29 2021-09-02 The University Of Vermon Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Endocrine-Related Cancer 6 (1999) str. 205-210 (abstrakt) *
Int. J. Cancer 55 str. 873-876 (1993) (abstrakt) *
J. Steroid Biochem. Molec. Biol. 67 (4) str. 293-304 (1998) (abstrakt) *
Journal of the National Cancer Institute 87 (10) 1995 str. 746-750 (abstrakt) *
Oncology Research 9 (8) str. 397-402 (1997) (abstrakt) *
The Breast 5 str. 192-195 (1996) (abstrakt) *

Also Published As

Publication number Publication date
EE05026B1 (et) 2008-06-16
AU4437201A (en) 2001-10-15
DE60113975D1 (de) 2006-02-23
IS6576A (is) 2002-10-01
PL201175B1 (pl) 2009-03-31
US20030158166A1 (en) 2003-08-21
EP1586323A1 (en) 2005-10-19
EP1272195A1 (en) 2003-01-08
IL151932A0 (en) 2003-04-10
JP2003528919A (ja) 2003-09-30
IS2869B (is) 2014-03-15
RU2265438C2 (ru) 2005-12-10
DK1272195T3 (da) 2006-01-16
CH1272195H1 (enExample) 2019-10-15
BR0109789A (pt) 2003-01-21
ATE306270T1 (de) 2005-10-15
NO20024735L (no) 2002-11-27
CZ20023309A3 (cs) 2003-02-12
MXPA02009744A (es) 2004-02-26
HU230064B1 (hu) 2015-06-29
ES2248300T3 (es) 2006-03-16
CN1431905A (zh) 2003-07-23
NO20024735D0 (no) 2002-10-02
EP1272195B1 (en) 2005-10-12
HUP0300339A2 (hu) 2003-06-28
US20110183949A1 (en) 2011-07-28
DE60113975T2 (de) 2006-06-22
AU2001244372B2 (en) 2006-02-16
ZA200207538B (en) 2003-12-19
KR20030007501A (ko) 2003-01-23
HUP0300339A3 (en) 2009-01-28
KR100757764B1 (ko) 2007-09-12
PL357936A1 (en) 2004-08-09
CA2403608A1 (en) 2001-10-11
NZ539603A (en) 2008-02-29
EE200200574A (et) 2004-04-15
GB0008172D0 (en) 2000-05-24
WO2001074366A1 (en) 2001-10-11
SK14292002A3 (sk) 2003-08-05
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A (en) 2007-07-04
UA80388C2 (en) 2007-09-25
HK1051498A1 (en) 2003-08-08

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
Beslija et al. Second consensus on medical treatment of metastatic breast cancer
JP2020522525A (ja) 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
Joffe et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report.
JP2023504436A (ja) 乳がんの治療のための併用療法
RU2320339C2 (ru) Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы
BG111123A (bg) Фулвестрант в доза от 500 мг за лечението на рак на гърдата в напреднал стадий
KR20250163966A (ko) 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
US20060241092A1 (en) Contraceptive regimens for lower-weight women
Palacios et al. Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
Milligan CONFIDENTIALITY STATEMENT
Kothari et al. The Treatment of Advanced Breast Cancer: Focus on Fulvestrant.
Howell et al. Endocrine therapy
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
Finigan et al. Hormones and fracture risk in postmenopausal women: The OPUS study

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20210402